uniQure Buys Back Rights To Hemophilia B Treatment In Europe

uniQure, a gene therapy developer, said it has reached a deal with the Chiesi Group to reacquire the rights to co-develop and commercialize its hemophilia B gene therapy in Europe and other select territories and to terminate their co-development and license agreement.

uniQure will be responsible for all future development costs, including approximately $3 million of expenses in 2017 that would have otherwise been shared with Chiesi. The company said it does not expect the transaction t impact its previous cash guidance and cash on hand should be sufficient to fund operations into 2019. uniQure expects to recognize Q3 deferred revenue of approximately $14 million from non-refundable payments received from Chiesi in 2013.

Leave a Comment